Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients
- PMID: 32927013
- DOI: 10.1016/j.jhin.2020.09.009
Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients
Abstract
Background: Pandrug-resistant Acinetobacter baumannii (PDRAB) is increasingly being reported as a nosocomial pathogen worldwide, but determining its clinical impact is challenging.
Aim: To assess the spectrum of excess mortality attributable to PDRAB infection in acute care settings.
Methods: This four-year cohort study was conducted in a tertiary-care referral hospital in Greece to estimate excess in-hospital mortality due to PDRAB infection by comparing patients infected to those colonized with PDRAB by means of competing risks survival analysis.
Findings: The study cohort comprised 91 patients (median age: 67 years; 77% men). For most patients, PDRAB was first isolated in the intensive care unit (ICU) (N = 51; 57%) or following ICU discharge (N = 26; 29%). Overall in-hospital mortality was 68% (95% confidence interval (CI): 57.5-77.5%). PDRAB-infected patients (N = 62; 68%) and PDRAB-colonized patients (N = 29; 32%) had similar baseline characteristics, but the absolute excess risk of 30-day mortality in infected patients compared to colonized patients was 34% (95% CI: 14-54%). Multivariable competing risks regression showed that PDRAB infection significantly increased the daily hazard of 30-day in-hospital death (cause-specific hazard ratio (csHR): 3.10; 95% CI: 1.33-7.21) while simultaneously decreasing the daily rate of discharge (csHR: 0.24; 95% CI: 0.08-0.74), thereby leading to longer hospitalization. Stronger effects were observed for bloodstream infections.
Conclusion: New effective antimicrobials would be expected to prevent mortality in one of every three patients treated for PDRAB infection and reduce their length of hospitalization. However, available therapeutic options remain extremely limited and emphasis on preventing healthcare-associated transmission of PDRAB is ever more important.
Keywords: Acinetobacter baumannii; Competing risks; Hospital epidemiology; Pandrug-resistant bacteria; Survival.
Copyright © 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patients.Clin Microbiol Infect. 2025 Jun;31(6):1033-1039. doi: 10.1016/j.cmi.2025.02.018. Epub 2025 Feb 18. Clin Microbiol Infect. 2025. PMID: 39978636
-
Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece.J Chemother. 2021 Sep;33(5):354-357. doi: 10.1080/1120009X.2020.1839689. Epub 2020 Oct 30. J Chemother. 2021. PMID: 33124498
-
Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan.J Formos Med Assoc. 2003 Sep;102(9):601-6. J Formos Med Assoc. 2003. PMID: 14625603
-
Therapeutic options for Acinetobacter baumannii infections.Expert Opin Pharmacother. 2008 Mar;9(4):587-99. doi: 10.1517/14656566.9.4.587. Expert Opin Pharmacother. 2008. PMID: 18312160 Review.
-
Treatment of Acinetobacter infections.Expert Opin Pharmacother. 2010 Apr;11(5):779-88. doi: 10.1517/14656561003596350. Expert Opin Pharmacother. 2010. PMID: 20210684 Review.
Cited by
-
Antimicrobial stewardship: a COVID casualty?J Hosp Infect. 2020 Nov;106(3):401-403. doi: 10.1016/j.jhin.2020.10.002. Epub 2020 Oct 9. J Hosp Infect. 2020. PMID: 33045312 Free PMC article. No abstract available.
-
Risk Factors for and Clinical Outcomes of Polymicrobial Acinetobacter baumannii Bloodstream Infections.Biomed Res Int. 2022 Feb 27;2022:5122085. doi: 10.1155/2022/5122085. eCollection 2022. Biomed Res Int. 2022. PMID: 35265714 Free PMC article.
-
Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii Isolated from the Intensive Care Unit in a Tertiary Teaching Hospital in Malaysia.Antibiotics (Basel). 2021 Nov 2;10(11):1340. doi: 10.3390/antibiotics10111340. Antibiotics (Basel). 2021. PMID: 34827278 Free PMC article.
-
Whole genome sequence of pan drug-resistant clinical isolate of Acinetobacter baumannii ST1890.PLoS One. 2022 Mar 9;17(3):e0264374. doi: 10.1371/journal.pone.0264374. eCollection 2022. PLoS One. 2022. PMID: 35263355 Free PMC article.
-
Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization.JAC Antimicrob Resist. 2023 Aug 10;5(4):dlad096. doi: 10.1093/jacamr/dlad096. eCollection 2023 Aug. JAC Antimicrob Resist. 2023. PMID: 37577156 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical